EMCDDA Home
  • EN
Search

EMCDDA publication series

Publications are the principal means by which the EMCDDA makes its work available to the Member States and the European Community. The agency has a set of publication products tailored to the needs of specific audiences and published in a variety of print or web formats.

The publications of the EMCDDA can be grouped under three general headings:

  • core publications consisting of the EMCDDA statutory publications, periodicals and series;
  • topical reports and studies;
  • and web-based information products presenting the most up-to-date data on the drug phenomenon.

A variety of brochures and catalogues are also produced to promote EMCDA products and raise the profile of the agency.

The characteristics of the following EMCDDA titles are outlined below:

 

Annual report

The Annual report on the state of the drugs problem in Europe presents the EMCDDA's yearly overview of the drug phenomenon. This is an essential reference book for policymakers, specialists and practitioners in the drugs field or indeed anyone seeking the latest findings on drugs in Europe. Published every autumn, the report contains non-confidential data supported by an extensive range of figures.

Target groups: Policymakers and their advisors (primary target); specialists and practitioners in the drugs field.

List all Annual reports >>

top of page

General report of activities

gra2007

The General report of activities is an annual publication providing a detailed progress report of the EMCDDA's activities over a 12-month period. It also includes the Authorising officer’s report and the declaration of assurance. Published every spring, it catalogues the Centre's achievements in each area of its annual work programme. The report is a useful information source for all those seeking comprehensive information on the Centre and its work.

Target groups: European institutions; EMCDDA statutory bodies; drug-related bodies in the EU Member States; international organisations.

List all General reports of activities >>

top of page

Drugnet Europe

Drugnet Europe, the EMCDDA's newsletter, provides regular, rapid and succinct information on the Centre's activities to a broad readership. There are four issues of Drugnet published per year.

The newsletter carries regular features highlighting the work of the national focal points, European and international institutions, and relevant action taken under the presidencies of the European Union in the field of drugs.

It is both an instrument of information (news) and a forum for communication between partners (exchange), and provides a complete overview of the work of the agency and its key partners.

Target groups: EMCDDA partners: focal points and international institutions; practitioners in drugs field; scientists and researchers; European citizens.

List all Drugnet Europe >>

top of page

Drugs in focus

Drugs in focus is the title of a series of policy briefings from the EMCDDA.

The four-page briefings are designed to offer policymakers the latest findings on key issues in the drugs field and to inform the decision-making process in this domain. Each edition includes a brief introduction to the theme at hand, key policy issues at a glance, graphs/tables, policy considerations, web information and further reading.

The briefings are published three times per year in the official EU languages plus Norwegian.

Target groups: Policymakers and their advisors.

List all Drugs in focus >>

top of page

Insights

The EMCDDA's Insights are volumes conveying the findings of study and research carried out by the agency on topical issues in the drugs field.

Target groups: Policymakers and their advisors; specialists and practitioners in the drugs field.

List all Insights >>

top of page

Literature reviews

Literature reviews bring the reader up-to-date with current knowledge on a particular topic, highlighting areas that still need research and development.

Target groups: Specialists and practitioners in the drugs field, including scientists and academics, policymakers.

List all Literature reviews >>

top of page

Monographs

The EMCDDA Monographs are specialised publications containing scientific papers prepared in the context of EMCDDA research studies, conferences and seminars.

The series aims to ensure greater visibility for the agency as a scientific authority in the drugs field. Topics cover a wide range of issues, from science, policy, theory and methods to practical cases and facts.

Target groups: Specialists and practitioners in the drugs field, including scientists and academics (primary target); policymakers and their advisors.

List all Monographs >>

top of page

Manuals

The EMCDDA's Manuals are practical handbooks aimed at professionals and grassroot practitioners working in the drugs field.

Target groups: Practitioners in the drugs field.

List all Manuals >>

top of page

National reports

Commissioned each year by the EMCDDA and produced by the national focal points of the Reitox network, the National reports draw an overall picture of the drug phenomenon at national level in each EU Member State. These data are key information to the EMCDDA and are an important resource, among others for the compilation of its Annual report.

Target groups
European institutions; international organisations; drug-related bodies in the EU Member States; EMCDDA statutory bodies; journalists, policymakers and their advisors; specialists and practitioners in the drugs field.

List all National reports >>

top of page

Risk assessments

Risk assessment reports present the outcome and the conclusions of the formal procedure to assess the health and social risks caused by the use of, the manufacture of, and traffic in, a new psychoactive substance. The risk assessment is carried out by the EMCDDA Scientific Committee, with participation of additional experts from the EU Member States, European Commission, Europol and the European Medicines Agency. Risk assessment reports are submitted to the Commission and the Council. On the basis of a risk assessment report (and at the initiative of the European Commission or a Member State), the Council of the EU may decide to subject the new psychoactive substance to control measures throughout the EU.

The EMCDDA has carried out formal risk assessments of a number of substances of concern to Member States (MBDB, 4-MTA, GHB, ketamine, PMMA, 2C-I, 2C-T-2, 2C-T-7, TMA-2, BZP and mephedrone). The findings of these exercises have been published along with guidelines on the information exchange and risk assessment on new psychoactive substances.

Risk assessment reports record the results of the agency's work under the terms of the Action on new drugs.

Target groups: European institutions, drug-related bodies in the EU Member States, and EMCDDA statutory bodies. International organisations, specialists in the drugs field, including scientists, academics, policymakers and journalists may also benefit from the reports.

List all Risk assessments >>

top of page

Selected issues

The Selected issues are in-depth reviews of topical interest. They are based on information provided to the EMCDDA by the Reitox national focal points as part of the national reporting process.

Target groups: Policymakers and their advisors; specialists and practitioners in the drugs field.

List all Selected issues >>

top of page

Thematic papers

The EMCDDA Thematic papers are scientific papers on selected, theme-based aspects of the drugs phenomenon. Designed for online dissemination via the Internet, the series is available only in pdf format.

Target groups: Specialists and practitioners in the drugs field, including scientists and academics, policy-makers.

List all Thematic papers >>

top of page

Technical datasheets

Technical datasheets present and discuss information on ongoing EMCDDA research topics.

Target groups: Specialists and practitioners in the drugs field, including scientists and academics.

List all Technical datasheets >>

top of page

Joint reports

Joint reports present the outcome of the EMCDDA and Europol formal collection of information on a new psychoactive substance, under the terms of the Council Decision 2005/387/JHA of 10 May 2005 on the information exchange, risk assessment and control of new psychoactive substances. Joint reports are submitted jointly by the EMCDDA and Europol to the Council of the EU, the European Commission and the European Medicines Agency. On the basis of a Joint report, the Council may request to launch a formal risk assessment procedure on the substance.

The EMCDDA has produced Joint reports on a number of substances not only under the terms of the Council Decision (mCPP, BZP and mephedrone), but also under the Joint action concerning the information exchange, risk assessment and control of new synthetic drugs (including MBDB, 4-MTA, GHB, ketamine, PMMA, 2C-I, 2C-T-2, 2C-T-7, and TMA-2).

Joint reports record the results of the agency's work under the terms of the Action on new drugs.

Target groups: European institutions, drug-related bodies in the EU Member States, and EMCDDA statutory bodies. International organisations, specialists in the drugs field, including scientists and academics and journalists may also benefit from the reports.

List all Joint reports >>

top of page

Implementation reports

Implementation reports present annually the results and the key issues arising from the implementation of the Council Decision 2005/387/JHA of 10 May 2005 on the information exchange, risk assessment and control of new psychoactive substances. Implementation reports are submitted jointly by the EMCDDA and Europol to the European Parliament, the Council and the Commission.

Implementation reports record the activities of the agency's work under the terms of the Action on new drugs.

Target groups: European institutions, drug-related bodies in the EU Member States, and EMCDDA statutory bodies. International organisations, specialists in the drugs field, including scientists and academics and journalists may also benefit from the reports.

List all Implementation reports >>

top of page

About the EMCDDA

The European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) is the reference point on drugs and drug addiction information in Europe. Inaugurated in Lisbon in 1995, it is one of the EU's decentralised agencies. Read more >>

Contact us

EMCDDA
Praça Europa 1, Cais do Sodré
1249-289 Lisbon
Portugal
Tel. (351) 211 21 02 00

More contact options >>

Page last updated: Wednesday, 17 December 2014